
Commentary|Videos|May 29, 2025
CMSC Live: 2025 Annual Meeting Day 2
Host Jeffrey Wilken, PhD, chats with Anthony Feinstein, MPhil, PhD, FRCP, about the second day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.
Advertisement
Host
- Jeffrey Wilken, PhD
President-Elect,Consortium of Multiple Sclerosis Centers (CMSC); assistant professor of neurology, Georgetown University; director of Research, Neuropsychology Associates of Fairfax; executive director, Washington Neuropsychology Research Group
Guest
- Anthony Feinstein, MPhil, PhD, FRCP
Professor of Psychiatry at the University of Toronto
Segment Breakdown
- 00:00 – Jeffrey Wilken, PhD, introduces Anthony Feinstein, MPhil, PhD, FRCP, and the topic of his Donald Paty lecture on depression in MS.
- 02:00 – Anthony Feinstein, MPhil, PhD, FRCP, notes the lack of sex-based differences in MS depression and absence of a genetic link, contrasting with general population trends.
- 04:00 – Structural and functional imaging show limbic system changes in patients with MS who are depressed, offering biological explanations for depression independent of life circumstances.
- 05:00 - Anthony Feinstein, MPhil, PhD, FRCP, highlights 2 promising drug and discusses strong evidence for internet-based CBT as well as the growing role of digital mental health tools.
- 07:30 - Anthony Feinstein, MPhil, PhD, FRCP, recommends combining therapy and medication, borrowing from general psychiatry, and notes that most patients with MS prefer psychotherapy, aligning with global mental health trends.
- 9:00 - Depression often goes undiagnosed or untreated in MS clinics and nurses or family members may notice depression first because of time-limited neurology visits.
- 10:30 - Anthony Feinstein, MPhil, PhD, FRCP, praises the meeting’s behavioral health focus and upcoming sessions on cognitive wellness and brain health. Emphasizes a shift toward supporting patient resilience and well-being, accelerated by the pandemic.
- 11:30 - Jeffrey Wilken, PhD, thanks Anthony Feinstein, MPhil, PhD, FRCP, for his lecture and conversation.
Advertisement
Related to this article

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis
2
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
3
New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy
4
TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome
5

